HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Rozrolimupab, symphobodies against rhesus D, for the potential prevention of hemolytic disease of the newborn and the treatment of idiopathic thrombocytopenic purpura.

Abstract
Currently under codevelopment by Symphogen and Swedish Orphan Biovitrum, rozrolimupab is the first in a new class of recombinant polyclonal antibodies, known as symphobodies, produced using a proprietary technology from Symphogen. Rozrolimupab is being investigated for the prevention of hemolytic disease of the fetus and newborn (HDFN) and for the treatment of idiopathic thrombocytopenic purpura (ITP). Rozrolimupab comprises 25 genetically unique IgG1 antibodies, all of which are specific for the rhesus D (RhD) erythrocyte protein. In preclinical studies, rozrolimupab demonstrated binding to erythrocytes that was comparable with that of two plasma-derived anti-D Ig preparations. In a phase I clinical trial in healthy male volunteers, treatment with rozrolimupab was not associated with serious adverse events. In a phase II clinical trial of rozrolimupab in healthy, male, RhD-negative volunteers, rozrolimupab dose-dependently cleared RhD-positive erythrocytes from the circulation. Phase II clinical trials in ITP and HDFN are currently ongoing. Phase III clinical trials are necessary to establish the efficacy and safety profile of rozrolimupab compared with standard plasma-derived anti-D Ig preparations.
AuthorsRoberto Stasi
JournalCurrent opinion in molecular therapeutics (Curr Opin Mol Ther) Vol. 12 Issue 6 Pg. 734-40 (Dec 2010) ISSN: 2040-3445 [Electronic] England
PMID21154165 (Publication Type: Journal Article)
Chemical References
  • Antibodies, Monoclonal
  • Immunoglobulin G
  • Isoantibodies
  • RHO(D) antibody
  • Recombinant Proteins
  • Rh-Hr Blood-Group System
  • Rho(D) Immune Globulin
  • Rho(D) antigen
  • rozrolimupab
Topics
  • Antibodies, Monoclonal (immunology, metabolism, therapeutic use)
  • Clinical Trials as Topic
  • Erythroblastosis, Fetal (immunology, prevention & control)
  • Erythrocytes (metabolism)
  • Humans
  • Immunoglobulin G (immunology, metabolism, therapeutic use)
  • Infant, Newborn
  • Isoantibodies (immunology, metabolism, therapeutic use)
  • Protein Binding
  • Purpura, Thrombocytopenic, Idiopathic (immunology, prevention & control)
  • Recombinant Proteins (immunology, metabolism, therapeutic use)
  • Rh-Hr Blood-Group System (immunology)
  • Rho(D) Immune Globulin

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: